Helomics® Launches the DEFENDER™ Live Cell Liquid Biopsy System

Sigue a La Opinión en Facebook

The DEFENDER™ Live Cell Liquid Biopsy System is the world’s only
live cell liquid biopsy to detect all components of a patient’s shedding
tumor

Novel Proprietary Component of Precision Cellular Analytical
Platform (PCAP™), Further Expanding its Comprehensive Tumor Profiling
Offering to Patients, Physicians, and Life Science Industry

PITTSBURGH & LONDON–(BUSINESS WIRE)–Helomics®
Corporation
, a privately-held, personalized healthcare company that
provides comprehensive tumor profiling utilizing proprietary live cell
and fixed cell products and services, announced today the launch of the DEFENDER™
Live Cell Liquid Biopsy System
, a novel proprietary component of
precision cellular analytical platform (PCAP™).

The DEFENDER Live Cell Liquid Biopsy System leverages Helomics’ 15 years
experience and proprietary science in the ex vivo
multi-dimensional culture of human primary or recurrent tumor cells in
combination with Helomics’ extensive genomic and proteomic analytical
capabilities and expertise. The result is a research and discovery
platform that will be used to further enhance Helomics’ tumor biology
research and the development of clinical test efforts with collaborators
and partner-clients in academia, and in the diagnostics and
pharmaceutical industries.

Neil J. Campbell, President & CEO of Helomics, said, “The DEFENDER Live
Cell Liquid Biopsy System is an important clinical research and soon to
be clinical tool that will lead to a better understanding of the
biophysical processes involved in tumor cell shedding, and to the rapid
identification and development of new anti-cancer therapies, new
treatment markers, and companion diagnostics. We can view and analyze
the real-time evolution of tumor metastasis during the proliferation
cell cycling of a patient’s tumor. Using our DEFENDER and CellFx
platforms, Helomics can investigate fundamental questions of tumor
biochemistry, pathology, and gene and protein expression. The
combination of these two powerful platforms enables a comprehensive
study of the biology of tumors on a highly personalized basis.”

About the DEFENDER™ Live Cell Liquid Biopsy System and CellFx™

The core of both the DEFENDER™ System and CellFx™ platform is Helomics’
ability to grow live human tumors in a proprietary multi-dimensional
tissue culture system. Both platforms permit the temporal analysis of
cellular shedding, gene expression, and protein expression associated
with tumor cell proliferation, tumor cell death, drug response, and/or
drug toxicity. Helomics’ proprietary ability to grow human tumors in
culture has been meticulously refined for more than 15 years and is
currently in its fourth generation of tumor biology elucidation.

About PCAP™

The PCAP™ platform is the basis of Helomics’ comprehensive tumor
profiling capability. The platform consists of a suite of technologies
for the live and fixed cell analysis of changes in a tumor’s gene
regulation, protein expression, and cellular morphology over time or
with treatment.

About Helomics® Corporation, Inc.

Helomics® is a comprehensive personalized healthcare company, bringing
the next generation of diagnostics to the oncology field. Helomics is
dedicated to improving patient outcomes by providing a personalized
comprehensive tumor profile utilizing a proprietary set of laboratory
platforms that leverage both live and fixed cellular based analysis
allowing physicians to characterize malignant tumors on a personalized
basis. Helomics’ novel molecular and cellular markers and bioinformatics
services support treatment decisions by providing vital information
based on the specific biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company
maintains two CLIA-certified laboratories. For more information please
visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks
and uncertainties. Market conditions and other important factors could
cause actual results to differ materially from those communicated in any
forward-looking statements, information disclosed in presentations,
conference calls or other public venues. We do not intend to update any
forward-looking statements after the date of this press release.

Contacts

Tiberend
Strategic Advisors, Inc.

Investors
Joshua
Drumm, Ph.D., 212-375-2664
jdrumm@tiberend.com
or
Media
Claire
Sojda, 212-375-2686
csojda@tiberend.com